sodium chloride 0.9 % intravenous infusion bp
teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.
calcium resonium calcium polystyrene sulfonate powder can
sanofi-aventis australia pty ltd - calcium polystyrene sulfonate, quantity: 999.3 mg/g - powder - excipient ingredients: vanillin; saccharin - calcium resonium is an ion-exchange resin. it is recommended for the treatment of hyperkalaemia associated with anuria and severe oliguria.,it is also used to treat hyperkalaemia in patients requiring dialysis and in patients on regular haemodialysis or on prolonged peritoneal dialysis.
rexonium calcium polystyrene sulfonate 99.8% powder
kck pharmaceutical industries sdn. bhd. - calcium polystyrene sulfonate -
sodium valproate wockhardt sodium valproate 1000 mg/10 ml solution for injection ampoule
wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.
sodium valproate wockhardt sodium valproate 400 mg/4 ml solution for injection ampoule
wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.
solystat powder for suspension
pendopharm division of pharmascience inc - sodium polystyrene sulfonate - powder for suspension - 1g - sodium polystyrene sulfonate 1g - potassium-removing agents
solystat suspension
pendopharm division of pharmascience inc - sodium polystyrene sulfonate - suspension - 250mg - sodium polystyrene sulfonate 250mg - potassium-removing agents
solystat suspension
pendopharm division of pharmascience inc - sodium polystyrene sulfonate - suspension - 250mg - sodium polystyrene sulfonate 250mg - potassium-removing agents
kayexalate powder for suspension
sanofi-aventis canada inc - sodium polystyrene sulfonate - powder for suspension - 1g - sodium polystyrene sulfonate 1g - potassium-removing agents
sodium bicarbonate solution
onpharma, inc. - sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - sodium bicarbonate 84 mg in 1 ml - sodium bicarbonate inj., 8.4% usp neutralizing additive solution is indicated to hasten onset of analgesia and reduce injection pain, by adjusting commercial preparations of lidocaine w/ epinephrine anesthetic solution to a more physiologic ph. not for use as a systemic alkalizer. barash pg, cullen bf, stoelting rk, clinical anesthesia (4th ed. 2001 lippincott williams and wilken). bhatt h, powell kj, jean da, first aid for the anesthesiology boards, an insider's guide (2011, mcgraw-hill medical). cepeda ms, tzortzopoulou a, thackrey m, hudcova j, arora gandhi p, schumann r., adjusting the ph of lidocaine for reducing pain on injection. cochrane database of systematic reviews 2010, issue 12. art. no.: cd006581. chu lf, clinical anesthesiology board review(2005, mcgraw-hill medical). malamed sf,handbook of local anesthesiology(5th ed. 2004, elsevier mosby). miller rd, miller's anesthesia (6th ed. 2004). stoelting rk, miller rd,basics of anesthesia(5th ed. 2007, churchill livingstone el